We are thrilled to have received funding from the NCI for high-throughput screening and validation of targeted radiosensitizers and biomarker discovery. We are looking forward to collaborating with other investigators in the Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC), which is tasked with accelerating the pace by at which molecular targeted drug/radiation combinations with greater efficacy than in the past are identified.
